24/7 Market News Snapshot 22 October, 2025 – Armata Pharmaceuticals, Inc. Common Stock (NYSE:ARMP)

October 22, 2025

DENVER, Colo., 22 October, 2025 (www.247marketnews.com) – (NYSE:ARMP) are discussed in this article.
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) has captured significant market attention with its remarkable performance today, opening at $3.50 and achieving a peak of $7.319, marking a notable 110.92% increase from the prior close of $3.47. The surge, buoyed by a trading volume of 1.68 million shares, reflects robust investor confidence and highlights a potential turning point for the company within the biotechnology sector.

This surge in share value comes on the heels of promising developments surrounding Armata’s investigational product, AP-SA02. The company recently announced encouraging results from its Phase 2a diSArm study, evaluating AP-SA02 as a treatment for complicated Staphylococcus aureus bacteremia. The findings, presented as part of a late-breaking oral session at IDWeek 2025™, revealed an 88% clinical response rate among patients receiving AP-SA02, compared to a 58% response in the placebo group. Impressively, there were no instances of treatment-related non-response or relapse within the AP-SA02 cohort, signaling its potential as a reliable therapeutic alternative.

Dr. Loren G. Miller, who presented the data, highlighted the study as a pioneering effort demonstrating the effectiveness of intravenous phage therapy in a randomized clinical setting for SAB. Dr. Deborah Birx, the CEO of Armata, commended the work of the research team and emphasized the promising path forward to initiate pivotal trials expected in 2026.

Furthermore, the AP-SA02 treatment displayed an excellent safety profile, featuring minimal adverse events, along with trends showcasing quicker patient recovery and reduced hospital stays. The identification of unique genomic variants within AP-SA02 further underscores its ability to adapt against various S. aureus strains. Armata Pharmaceuticals is reaffirming its commitment to advancing phage therapy, setting the stage for transformative solutions to combat antibiotic-resistant infections in infectious disease management.

Related news for (ARMP)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.